Sign inJoin waitlistJoin the waitlist

Stephane Champiat

Associate Professor, Investigational Cancer Therapeutics · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present

Medical Oncology
2014–2016
Doctor of Medicine
2010–2014
2012-2013 Medical Oncology Resident
2012–2013

Research

Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Review · European Journal of Cancer · 2016 · 1,709 citations
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
The Lancet Oncology · 2018 · 978 citations
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Clinical Cancer Research · 2017 · First of 11 authors · 962 citations

LD
Laurent Dercle
10 papers · 4 as a resident
Ecaterina Dumbrava
8 papers · 2 as a fellow
Aung Naing
7 papers
Funda Meric-Bernstam
6 papers
David Hong
5 papers
Sarina Piha-Paul
5 papers
Siqing Fu
5 papers
Timothy Yap
5 papers
Apostolia Tsimberidou
4 papers
Tin-Yun Tang
4 papers · 1 as a fellow
Cristina Natha
3 papers · 3 as a resident
Hossein Borghaei
3 papers

Clinical trials

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Principal investigator · Terminated · Phase 1
SOTIO Biotech AG
2019–2024
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
Site PI · Recruiting · Phase 1
OncoC4, Inc.
2026–2028
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Takeda
2025–2029